139 related articles for article (PubMed ID: 1969381)
1. Protooncogene amplification and tumor ploidy in human ovarian neoplasms.
Sasano H; Garrett CT; Wilkinson DS; Silverberg S; Comerford J; Hyde J
Hum Pathol; 1990 Apr; 21(4):382-91. PubMed ID: 1969381
[TBL] [Abstract][Full Text] [Related]
2. Serous papillary adenocarcinoma of the endometrium. Analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry.
Sasano H; Comerford J; Wilkinson DS; Schwartz A; Garrett CT
Cancer; 1990 Apr; 65(7):1545-51. PubMed ID: 1690076
[TBL] [Abstract][Full Text] [Related]
3. DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis.
Diebold J; Suchy B; Baretton GB; Blasenbreu S; Meier W; Schmidt M; Rabes H; Löhrs U
Virchows Arch; 1996 Nov; 429(4-5):221-7. PubMed ID: 8972757
[TBL] [Abstract][Full Text] [Related]
4. [The significance of c-erbB-2 and int-2 gene alterations and DNA ploidy pattern for aggressiveness of breast cancer].
Nagayama K; Watatani M; Maeda S; Imanishi Y; Kurooka K; Wada T; Yasutomi M
Nihon Geka Gakkai Zasshi; 1993 Oct; 94(10):1144-52. PubMed ID: 7901748
[TBL] [Abstract][Full Text] [Related]
5. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.
Ottestad L; Andersen TI; Nesland JM; Skrede M; Tveit KM; Nustad K; Børresen AL
Acta Oncol; 1993; 32(3):289-94. PubMed ID: 8100712
[TBL] [Abstract][Full Text] [Related]
6. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines.
Tyson FL; Boyer CM; Kaufman R; O'Briant K; Cram G; Crews JR; Soper JT; Daly L; Fowler WC; Haskill JS
Am J Obstet Gynecol; 1991 Sep; 165(3):640-6. PubMed ID: 1679963
[TBL] [Abstract][Full Text] [Related]
7. [Amplification of c-myc proto-oncogene in primary tumors, metastases and blood leukocytes of patients with ovarian cancer].
Serova OM
Eksp Onkol; 1987; 9(1):25-7. PubMed ID: 3028756
[TBL] [Abstract][Full Text] [Related]
8. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
[TBL] [Abstract][Full Text] [Related]
9. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
10. Analysis of oncogenes and tumor suppressor genes in human breast cancer.
Yamashita H; Kobayashi S; Iwase H; Itoh Y; Kuzushima T; Iwata H; Itoh K; Naito A; Yamashita T; Masaoka A
Jpn J Cancer Res; 1993 Aug; 84(8):871-8. PubMed ID: 8104920
[TBL] [Abstract][Full Text] [Related]
11. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.
Berns EM; Klijn JG; van Staveren IL; Portengen H; Noordegraaf E; Foekens JA
Eur J Cancer; 1992; 28(2-3):697-700. PubMed ID: 1350457
[TBL] [Abstract][Full Text] [Related]
13. DNA amplifications and elevated expression of proto-oncogene in addition to altered DNA ploidy in metastatic brain tumors.
Arai T; Ichimura K; Hirakawa K; Yuasa Y
Clin Exp Metastasis; 1994 Jul; 12(4):267-75. PubMed ID: 7913669
[TBL] [Abstract][Full Text] [Related]
14. Hormonal activity of epithelial ovarian tumours in post-menopausal women.
Heinonen PK; Mörsky P; Aine R; Koivula T; Pystynen P
Maturitas; 1988 Mar; 9(4):325-38. PubMed ID: 3380017
[TBL] [Abstract][Full Text] [Related]
15. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
[TBL] [Abstract][Full Text] [Related]
16. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.
Seki A; Yoshinouchi M; Seki N; Kodama J; Miyagi Y; Kudo T
Int J Oncol; 2000 Jul; 17(1):103-6. PubMed ID: 10853025
[TBL] [Abstract][Full Text] [Related]
17. [Alterations of c-Myc and c-erbB-2 genes in ovarian tumours].
Pastor T; Popović B; Gvozdenović A; Boro A; Petrović B; Novaković I; Puzović D; Luković L; Milasin J
Srp Arh Celok Lek; 2009; 137(1-2):47-51. PubMed ID: 19370966
[TBL] [Abstract][Full Text] [Related]
18. [A study of amplifications of myc gene (c-myc and N-myc) in human ovarian cancer].
Kataoka A; Yakushiji M; Kojiro M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Mar; 42(3):259-63. PubMed ID: 2332674
[TBL] [Abstract][Full Text] [Related]
19. Interphase cytogenetic analysis of mucinous ovarian neoplasms.
Diebold J; Siegert S; Baretton GB; Suchy B; Meier W; Haas CJ; Löhrs U
Lab Invest; 1997 May; 76(5):661-70. PubMed ID: 9166285
[TBL] [Abstract][Full Text] [Related]
20. Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer.
Watson JV; Curling OM; Munn CF; Hudson CN
Gynecol Oncol; 1987 Oct; 28(2):137-50. PubMed ID: 3311922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
